Incyte reported net sales of $1.1 billion, up 20% from the prior year period. Management reiterated its 2026 guidance of net sales of $4.85 billion at the midpoint, up 11% from 2025. Key dermatology drug Opzelura generated sales of $143 million in the quarter, up 20% year over year.
Incyte's Jakafi is the first FDA-approved treatment for a rare blood disorder known as myelofibrosis, giving it strong pricing power and market penetration.
Several competing myelofibrosis therapies are entering the market and could upend Incyte's monopoly on the myelofibrosis market.
|
Metric
|
INCY
|
RHHBY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 13.76 | 16.19 | 8.51 |
Price/Book Value | 3.64 | 7.68 | 1.65 |
Price/Sales | 3.87 | 4.34 | 2.35 |
Price/Cash Flow | 9.67 | 14.23 | 8.69 |
|
Metric
|
INCY
|
RHHBY
|
PFE
|
|---|---|---|---|
Quick Ratio | 3.40 | 1.10 | 0.85 |
Current Ratio | 3.68 | 1.38 | 1.25 |
Interest Coverage | 710.24 | 13.46 | 3.73 |
|
Metric
|
INCY
|
RHHBY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 23.45% | 15.77% | 8.40% |
Return on Equity (Normalized) | 32.44% | 49.73% | 19.47% |
Return on Invested Capital (Normalized) | 30.19% | 23.68% | 12.80% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bkgknzqys | Kttfxd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fmsxrwwfw | Zcqxkk | $67B | |||
| argenx SE ADR
ARGX
| Khrpmwrh | Lxplb | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kblscbs | Zfcdrl | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Sxfqgkywgk | Jjvyym | $25B | |||
| BioNTech SE ADR
BNTX
| Gdblrjkxw | Gjgnv | $22B | |||
| Moderna Inc
MRNA
| Vslyrycz | Zvds | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qkgmzqn | Pzqlm | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Czlmsxp | Fqqgb | $13B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
United States